Results of intensive therapy in children with localized alveolar extremity rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study

R. Heyn, M. Beltangady, D. Hays, W. Lawrence, W. Newton, W. Crist, M. Tefft, H. M. Maurer

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Preliminary analyses of treatment results and prognostic factors from the first Intergroup Rhabdomyosarcoma Study (IRS I) suggested that alveolar histology and extremity site were among factors associated with an adverse outcome in clinical group I patients whose tumors had been completely resected. A high incidence of alveolar histology among the extremity tumors compounded the problem. These findings prompted an amendment to IRS II shortly after the study opened. Therapy for patients with alveolar extremity tumors in groups I and II was changed to more intensive repetitive pulse vincristine, dactinomycin, and cyclophosphamide (VAC) for 2 years. The outcome of 44 patients who received intensive therapy on IRS II is compared with a control series of 30 patients who were treated on IRS I. The control patients received standard VAC therapy for 2 years or VA for 1 year. Half of group I control patients received local radiotherapy, whereas none was given to group I intensive therapy patients. In both studies group II patients received radiotherapy to the primary tumor site and to identified positive regional lymph nodes. Compared with the control group, patients given more intensive therapy had a longer disease-free survival (DFS) (69% v 43% at 3 years), but this was of marginal significance (P = .06). The overall survival difference (77% v 57% at 3 years) was not significant (P = .23). Despite the limited statistical evidence, there is some indication that intensive therapy improved the prognosis of children with localized alveolar rhabdomyosarcoma (RMS).

Original languageEnglish (US)
Pages (from-to)200-207
Number of pages8
JournalJournal of Clinical Oncology
Volume7
Issue number2
DOIs
StatePublished - Jan 1 1989

Fingerprint

Alveolar Rhabdomyosarcoma
Rhabdomyosarcoma
Extremities
Therapeutics
Dactinomycin
Vincristine
Cyclophosphamide
Neoplasms
Histology
Radiotherapy
Pyridinolcarbamate
Control Groups
Disease-Free Survival
Lymph Nodes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Results of intensive therapy in children with localized alveolar extremity rhabdomyosarcoma : A report from the Intergroup Rhabdomyosarcoma Study. / Heyn, R.; Beltangady, M.; Hays, D.; Lawrence, W.; Newton, W.; Crist, W.; Tefft, M.; Maurer, H. M.

In: Journal of Clinical Oncology, Vol. 7, No. 2, 01.01.1989, p. 200-207.

Research output: Contribution to journalArticle

Heyn, R. ; Beltangady, M. ; Hays, D. ; Lawrence, W. ; Newton, W. ; Crist, W. ; Tefft, M. ; Maurer, H. M. / Results of intensive therapy in children with localized alveolar extremity rhabdomyosarcoma : A report from the Intergroup Rhabdomyosarcoma Study. In: Journal of Clinical Oncology. 1989 ; Vol. 7, No. 2. pp. 200-207.
@article{24785d84eb9846ebb07cbcbc35115f93,
title = "Results of intensive therapy in children with localized alveolar extremity rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study",
abstract = "Preliminary analyses of treatment results and prognostic factors from the first Intergroup Rhabdomyosarcoma Study (IRS I) suggested that alveolar histology and extremity site were among factors associated with an adverse outcome in clinical group I patients whose tumors had been completely resected. A high incidence of alveolar histology among the extremity tumors compounded the problem. These findings prompted an amendment to IRS II shortly after the study opened. Therapy for patients with alveolar extremity tumors in groups I and II was changed to more intensive repetitive pulse vincristine, dactinomycin, and cyclophosphamide (VAC) for 2 years. The outcome of 44 patients who received intensive therapy on IRS II is compared with a control series of 30 patients who were treated on IRS I. The control patients received standard VAC therapy for 2 years or VA for 1 year. Half of group I control patients received local radiotherapy, whereas none was given to group I intensive therapy patients. In both studies group II patients received radiotherapy to the primary tumor site and to identified positive regional lymph nodes. Compared with the control group, patients given more intensive therapy had a longer disease-free survival (DFS) (69{\%} v 43{\%} at 3 years), but this was of marginal significance (P = .06). The overall survival difference (77{\%} v 57{\%} at 3 years) was not significant (P = .23). Despite the limited statistical evidence, there is some indication that intensive therapy improved the prognosis of children with localized alveolar rhabdomyosarcoma (RMS).",
author = "R. Heyn and M. Beltangady and D. Hays and W. Lawrence and W. Newton and W. Crist and M. Tefft and Maurer, {H. M.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1200/JCO.1989.7.2.200",
language = "English (US)",
volume = "7",
pages = "200--207",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Results of intensive therapy in children with localized alveolar extremity rhabdomyosarcoma

T2 - A report from the Intergroup Rhabdomyosarcoma Study

AU - Heyn, R.

AU - Beltangady, M.

AU - Hays, D.

AU - Lawrence, W.

AU - Newton, W.

AU - Crist, W.

AU - Tefft, M.

AU - Maurer, H. M.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Preliminary analyses of treatment results and prognostic factors from the first Intergroup Rhabdomyosarcoma Study (IRS I) suggested that alveolar histology and extremity site were among factors associated with an adverse outcome in clinical group I patients whose tumors had been completely resected. A high incidence of alveolar histology among the extremity tumors compounded the problem. These findings prompted an amendment to IRS II shortly after the study opened. Therapy for patients with alveolar extremity tumors in groups I and II was changed to more intensive repetitive pulse vincristine, dactinomycin, and cyclophosphamide (VAC) for 2 years. The outcome of 44 patients who received intensive therapy on IRS II is compared with a control series of 30 patients who were treated on IRS I. The control patients received standard VAC therapy for 2 years or VA for 1 year. Half of group I control patients received local radiotherapy, whereas none was given to group I intensive therapy patients. In both studies group II patients received radiotherapy to the primary tumor site and to identified positive regional lymph nodes. Compared with the control group, patients given more intensive therapy had a longer disease-free survival (DFS) (69% v 43% at 3 years), but this was of marginal significance (P = .06). The overall survival difference (77% v 57% at 3 years) was not significant (P = .23). Despite the limited statistical evidence, there is some indication that intensive therapy improved the prognosis of children with localized alveolar rhabdomyosarcoma (RMS).

AB - Preliminary analyses of treatment results and prognostic factors from the first Intergroup Rhabdomyosarcoma Study (IRS I) suggested that alveolar histology and extremity site were among factors associated with an adverse outcome in clinical group I patients whose tumors had been completely resected. A high incidence of alveolar histology among the extremity tumors compounded the problem. These findings prompted an amendment to IRS II shortly after the study opened. Therapy for patients with alveolar extremity tumors in groups I and II was changed to more intensive repetitive pulse vincristine, dactinomycin, and cyclophosphamide (VAC) for 2 years. The outcome of 44 patients who received intensive therapy on IRS II is compared with a control series of 30 patients who were treated on IRS I. The control patients received standard VAC therapy for 2 years or VA for 1 year. Half of group I control patients received local radiotherapy, whereas none was given to group I intensive therapy patients. In both studies group II patients received radiotherapy to the primary tumor site and to identified positive regional lymph nodes. Compared with the control group, patients given more intensive therapy had a longer disease-free survival (DFS) (69% v 43% at 3 years), but this was of marginal significance (P = .06). The overall survival difference (77% v 57% at 3 years) was not significant (P = .23). Despite the limited statistical evidence, there is some indication that intensive therapy improved the prognosis of children with localized alveolar rhabdomyosarcoma (RMS).

UR - http://www.scopus.com/inward/record.url?scp=0024499184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024499184&partnerID=8YFLogxK

U2 - 10.1200/JCO.1989.7.2.200

DO - 10.1200/JCO.1989.7.2.200

M3 - Article

C2 - 2915235

AN - SCOPUS:0024499184

VL - 7

SP - 200

EP - 207

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -